Jul 7, 2008 - Archemix Corp., a biotechnology company focused on discovering, developing and commercializing aptamer therapeutics for rare hematological diseases, today announced that ARC1779 has received orphan drug designation from the European Commission (EC). ARC1779 also received orphan drug designation from the U.S. Food and Drug Administration (FDA) in April 2008.
An orphan designation in the European Union confers a range of benefits to sponsor companies including market exclusivity for a period of 10 years, EMEA scientific advice on protocol development, direct access to the centralized procedure for review of marketing authorizations, EMEA fee reductions and eligibility for grant support from European agencies.
The whole story can be read here.
No comments:
Post a Comment